BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim DJ, Kim HS, Oh M, Kim EY, Shin JG. Cost Effectiveness of Genotype-Guided Warfarin Dosing in Patients with Mechanical Heart Valve Replacement Under the Fee-for-Service System. Appl Health Econ Health Policy 2017;15:657-67. [PMID: 28247199 DOI: 10.1007/s40258-017-0317-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 de Oliveira Magalhães Mourão A, Braga Gomes K, Afonso Reis E, Pedra de Souza R, de Freitas Campos EI, Dias Ribeiro D, da Costa Rocha MO, Parreiras Martins MA. Algorithm for predicting low maintenance doses of warfarin using age and polymorphisms in genes CYP2C9 and VKORC1 in Brazilian subjects. Pharmacogenomics J 2020;20:104-13. [PMID: 31395958 DOI: 10.1038/s41397-019-0091-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
2 Tavares LC, Marcatto LR, Santos PCJL. Genotype-guided warfarin therapy: current status. Pharmacogenomics 2018;19:667-85. [PMID: 29701078 DOI: 10.2217/pgs-2017-0207] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
3 Tse G, Gong M, Li G, Wong SH, Wu WKK, Wong WT, Roever L, Lee APW, Lip GYH, Wong MCS, Liu T; International Health Informatics Study (IHIS) Network. Genotype-guided warfarin dosing vs. conventional dosing strategies: a systematic review and meta-analysis of randomized controlled trials. Br J Clin Pharmacol 2018;84:1868-82. [PMID: 29704269 DOI: 10.1111/bcp.13621] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
4 Turongkaravee S, Jittikoon J, Rochanathimoke O, Boyd K, Wu O, Chaikledkaew U. Pharmacogenetic testing for adverse drug reaction prevention: systematic review of economic evaluations and the appraisal of quality matters for clinical practice and implementation. BMC Health Serv Res 2021;21:1042. [PMID: 34600523 DOI: 10.1186/s12913-021-07025-8] [Reference Citation Analysis]
5 Li X, Li D, Wu JC, Liu ZQ, Zhou HH, Yin JY. Precision dosing of warfarin: open questions and strategies. Pharmacogenomics J 2019;19:219-29. [PMID: 30745565 DOI: 10.1038/s41397-019-0083-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
6 Zhu Y, Swanson KM, Rojas RL, Wang Z, St Sauver JL, Visscher SL, Prokop LJ, Bielinski SJ, Wang L, Weinshilboum R, Borah BJ. Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases. Genet Med 2020;22:475-86. [PMID: 31591509 DOI: 10.1038/s41436-019-0667-y] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
7 Eljilany I, Elewa H, Al-Badriyeh D. Cost-Benefit Analysis of Genotype-Guided Interruption Days in Warfarin Pre-Procedural Management. Curr Probl Cardiol 2022;:101128. [PMID: 35114296 DOI: 10.1016/j.cpcardiol.2022.101128] [Reference Citation Analysis]
8 Nguyen VL, Nguyen HD, Cho YS, Kim HS, Han IY, Kim DK, Ahn S, Shin JG. Comparison of multivariate linear regression and a machine learning algorithm developed for prediction of precision warfarin dosing in a Korean population. J Thromb Haemost 2021;19:1676-86. [PMID: 33774911 DOI: 10.1111/jth.15318] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Wang L, Liu L, Liu X, Xiang M, Zhou L, Huang C, Shen Z, Miao L. The gut microbes, Enterococcus and Escherichia-Shigella, affect the responses of heart valve replacement patients to the anticoagulant warfarin. Pharmacol Res 2020;159:104979. [PMID: 32505835 DOI: 10.1016/j.phrs.2020.104979] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]